Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction

American Journal of Cardiology

Volumn 106, Issue 4, 2010, Pages 477-482

  Kelly, Dominic ^a   Squire, Iain B ^a   Khan, Sohail Q ^a   Dhillon, Onkar ^a   Narayan, Hafid ^a   Ng, K H ^a   Quinn, Paulene ^a   Davies, Joan E ^a   Ng, Leong L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; FUROSEMIDE; INOTROPIC AGENT; NITRATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; BIOLOGICAL MARKER; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE-4;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; DRUG MEGADOSE; ELECTROCARDIOGRAM; ENZYME BLOOD LEVEL; FEMALE; FIBRINOLYTIC THERAPY; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; AGED; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; COMPLICATION; HEART INFARCTION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES; YOUNG ADULT;

EID: 77955449211     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.03.060     Document Type: Article

References (21)

1. K.A. Eagle, M.J. Lim, O.H. Dabbous, K.S. Pieper, R.J. Goldberg, F. Van de Werf, S.G. Goodman, C.B. Granger, P.G. Steg, J.M. Gore, A. Budaj, A. Avezum, M.D. Flather, and K.A. Fox A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry JAMA 291 2004 2727 2733 (Pubitemid 38725422)
2. K.A. Fox, O.H. Dabbous, R.J. Goldberg, K.S. Pieper, K.A. Eagle, F. Van de Werf, A. Avezum, S.G. Goodman, M.D. Flather, F.A. Anderson Jr, and C.B. Granger Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ 333 2006 1091
3. N. Arakawa, M. Nakamura, H. Aoki, and K. Hiramori Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction J Am Coll Cardiol 27 1996 1656 1661
4. T. Omland, A. Persson, L. Ng, R. O'Brien, T. Karlsson, J. Herlitz, M. Hartford, and K. Caidahl N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes Circulation 106 2002 2913 2918
5. R.J. O'Brien, I.B. Squire, B. Demme, J.E. Davies, and L.L. Ng Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF Eur J Heart Fail 5 2003 499 506
6. A.M. Richards, M.G. Nicholls, T.G. Yandle, C. Frampton, E.A. Espiner, J.G. Turner, R.C. Buttimore, J.G. Lainchbury, J.M. Elliott, H. Ikram, I.G. Crozier, and D.W. Smyth Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction Circulation 97 1998 1921 1929
7. D.E. Gomez, D.F. Alonso, H. Yoshiji, and U.P. Thorgeirsson Tissue inhibitors of metalloproteinases: structure, regulation and biological functions Eur J Cell Biol 74 1997 111 122
8. E. Lubos, R. Schnabel, H.J. Rupprecht, C. Bickel, C.M. Messow, S. Prigge, F. Cambien, L. Tiret, T. Munzel, and S. Blankenberg Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study Eur Heart J 27 2006 150 156
9. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
10. D. Kelly, G. Cockerill, L.L. Ng, M. Thompson, S. Khan, N.J. Samani, and I.B. Squire Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study Eur Heart J 28 2007 711 718
11. D. Kelly, S. Khan, G. Cockerill, L.L. Ng, M. Thompson, N.J. Samani, and I.B. Squire Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction Eur J Heart Fail 10 2008 133 139
12. D. Kelly, S.Q. Khan, M. Thompson, G. Cockerill, L.L. Ng, N. Samani, and I.B. Squire Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction Eur Heart J 29 2008 2116 2124
13. D.L. Brown, M.S. Hibbs, M. Kearney, C. Loushin, and J.M. Isner Identification of 92-kD gelatinase in human coronary atherosclerotic lesions Association of active enzyme synthesis with unstable angina Circulation 91 1995 2125 2131
14. C.S. Webb, D.D. Bonnema, S.H. Ahmed, A.H. Leonardi, C.D. McClure, L.L. Clark, R.E. Stroud, W.C. Corn, L. Finklea, M.R. Zile, and F.G. Spinale Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling Circulation 114 2006 1020 1027
15. W.H. Yu, S. Yu, Q. Meng, K. Brew, and J.F. Woessner Jr TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix J Biol Chem 275 2000 31226 31232
16. S. Heymans, B. Schroen, P. Vermeersch, H. Milting, F. Gao, A. Kassner, H. Gillijns, P. Herijgers, W. Flameng, P. Carmeliet, F. Van de Werf, Y.M. Pinto, and S. Janssens Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart Circulation 112 2005 1136 1144
17. E. Elmas, S. Lang, C.E. Dempfle, T. Kalsch, D. Hannak, T. Sueselbeck, C. Wolpert, M. Borggrefe, and M. Brueckmann High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction Clin Chem Lab Med 45 2007 1360 1365
18. A.Y. Strongin, I. Collier, G. Bannikov, B.L. Marmer, G.A. Grant, and G.I. Goldberg Mechanism of cell surface activation of 72-kDa type IV collagenase Isolation of the activated form of the membrane metalloprotease J Biol Chem 270 1995 5331 5338
19. B. Bertaux, W. Hornebeck, A.Z. Eisen, and L. Dubertret Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases J Invest Dermatol 97 1991 679 685
20. E. Lambert, E. Dasse, B. Haye, and E. Petitfrere TIMPs as multifacial proteins Crit Rev Oncol/Hematol 49 2004 187 198
21. M.P. Hudson, P.W. Armstrong, W. Ruzyllo, J. Brum, L. Cusmano, P. Krzeski, R. Lyon, M. Quinones, P. Theroux, D. Sydlowski, H.E. Kim, M.J. Garcia, W.A. Jaber, and W.D. Weaver Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial J Am Coll Cardiol 48 2006 15 20